Episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials. Pharmacotherapy 2009;29:7841.S55 OnabotulinumtoxinA for migraine

Episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials. Pharmacotherapy 2009;29:7841.S55 OnabotulinumtoxinA for migraine treatment Andrea Negro1,two ([email protected]) 1 Regional Referral Headache Centre, Sant’Andrea Hospital, By means of di Grottarossa 1035-1039, 00191; 2Department of Clinical and Molecular Medicine, Sapienza University of Rome, Italy The Journal of Headache and Discomfort 2017, 18(Suppl 1):S55 Given that 2010 the armamentarium of preventative drugs for chronic migraine (CM) has develop into wider with all the introduction of OnabotulinumtoxinA (Botox. The European Headache Federation recognized the value of OnabotulinumtoxinA suggesting that, before labeling a patient as affected by refractory CM, a right therapy with this drug desires to become completed [1]. In the final years several real-life prospective research provided further proof in clinical setting of OnabotulinumtoxinA 155-195 U efficacy for the headache prophylaxis in CM difficult by medication overuse headache (MOH) [2]. Recently we published the outcomes of a potential study on the longterm (two years) efficacy and security of a single dose of OnabotulinumtoxinA (155 or 195 U) in patients with CM plus MOH had failed preceding preventative drugs and detoxification attempts [3]. Both the doses have been helpful and equally secure, but 195 U was extra effective than 155 U in reducing headache days, migraine days, pain medication intake days and Headache Chlormidazole Epigenetic Reader Domain Impact Test (HIT)-6 score. A lot more,S56 Trigeminal autonomic cephalalgias (TACs) Ferdinando Maggioni ([email protected]) Headache Centre, Department of Neurosciences, University of Padua, Italy The Journal of Headache and Discomfort 2017, 18(Suppl 1):S56 Trigeminal autonomic cephalalgias (TACs) are a group of major headaches comprehending the following syndromes: episodic and chronic cluster headache (CH), episodic and chronic paroxysmal hemicrania (PH), short-lasting unilateral neuralgiform headache attacks, and hemicrania continua(HC) [1]. Their phenotypes are comparable and attack duration would be the most important feature distinguishing the very first three TACs. An correct diagnosis is important for the reason that of their diverse response to treatment options. Among TACs, CH is most typical; on the other hand TACs are about at the least 100 occasions much less frequent than migraine. CH prevalence in adults is 1 and interests specially the male population. CH normally happens at the exact same time with the day, from once to eight times each day, and within the identical period from the year. CH is featured by extreme unilateral peri-orbital and or temporal pain lasting from 15 to 180 ��-Bisabolene Inhibitor minutes if untreated, linked with at the least 1 autonomic symptom (conjunctival injection, lacrimation, nasal congestion, rhinorrhea, facial sweating, miosis, ptosis and eyelid edema). Trigger elements can include things like alcohol, volatile chemicals or perhaps a warm atmosphere (three). Acute therapy consists of the use of oxygen at a price of 12-15Lmin for no less than 15 minutes and triptans. Controlled trials have investigated the efficacy of subcutaneous sumatriptan, nasal sumatriptan, and nasal zolmitriptan. When a preventiveThe Journal of Headache and Pain 2017, 18(Suppl 1):Web page 20 ofmedication is expected, verapamil may be the reference remedy. PH attack functions are characterized by unilateral, normally stabbing, headaches, shorter and more frequent than in cluster headaches. PH is responsive to remedy with indomethacin. Indomethacin dosages ranges from 25 to 75 mg, three occasions each day. SUNCT.